TX1-85-1

CAS No. 1603845-32-4

TX1-85-1 ( —— )

Catalog No. M23702 CAS No. 1603845-32-4

TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 140 In Stock
10MG 250 In Stock
25MG 401 In Stock
50MG 591 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TX1-85-1
  • Note
    Research use only, not for human use.
  • Brief Description
    TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
  • Description
    TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. TX1-85-1 is an irreversible Her3 inhibitor (IC50: 23 nM). TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    ErbB3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1603845-32-4
  • Formula Weight
    580.7
  • Molecular Formula
    C32H36N8O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:3.85 mg/mL (6.63 mM; Need ultrasonic)
  • SMILES
    CC(N1CCN(C2CCC(N3N=C(C4=CC(NC(C=C)=O)=C(OC5=CC=CC=C5)C=C4)C6=C3N=CN=C6N)CC2)CC1)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Xie T, et al. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol. 2014 Dec;10(12):1006-12.
molnova catalog
related products
  • BMS-690514

    A potent pan HER/VEGFR inhibitor with IC50 of 5/20/60/50 nM for EGFR/HER2/ERBB4/VEGFR2 respectively.

  • Olmutinib

    Olmutinib is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorOlmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.?

  • (Rac)-JBJ-04-125-02

    JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.